Abstract:

With the global prevalence of metabolic diseases increasing year by year, metabolism related non-alcoholic fatty liver disease (NAFLD) has become the most common chronic liver disease. NAFLD disease spectrum included initial liver steatosis, advanced non-alcoholic steatohepatitis (NASH), liver cirrhosis and hepatocellular carcinoma (HCC). In NASH stage, lipotoxicity and inflammatory damage of hepatocytes greatly increase the risk of end-stage liver disease. So far, there have been more than 1400 clinical trials for the treatment of Nash worldwide, but no specifi c drugs have been approved with no eff ective treatment for NASH related HCC. Even for emerging immunotherapy, NASH related HCC also showed signifi cant resistance to immunotherapy. The changes of immune microenvironment mediated by innate and adaptive immune cell subsets play an important role in the onset and progression of NASH. Thi s review focuses on the mechanism of a variety of immune cells in NASH and the research status of related immunotherapy, in order to provide reference for understanding the immune microenvironment of NASH and exploring new research directions.

Key words: Non-alcoholic steatohepatitis, Immune cell, Innate immunity, Adaptive immunity, Therapy